Business Wire

MILREM-ROBOTICS

30.6.2021 09:02:13 CEST | Business Wire | Press release

Share
iMUGS Consortium Demonstrated Manned-Unmanned Teaming Capabilities, Led by Milrem Robotics

The consortium behind iMUGS, a 32,6 MEUR project with the aim of developing the European standard unmanned ground system (UGS), demonstrated the results of the first phase of the project – deploying unmanned systems to the battlefield and teaming them with manned units and vehicles. The demonstration was spearheaded by the coordinator of the consortium, Europe’s leading developer of robotics and autonomous systems Milrem Robotics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210630005046/en/

During iMUGS (integrated Modular Unmanned Ground System) a modular, cyber secure and scalable architecture for hybrid manned-unmanned systems will be developed to standardize a European wide ecosystem for aerial and ground platforms, command, control and communication equipment, sensors, payloads, and algorithms. Addressed operational challenges include enhanced interoperability, increased situational awareness and faster decision-making.

The system will utilize an existing unmanned ground vehicle – Milrem Robotics’ THeMIS – and a specific list of payloads.

"The main objective of the iMUGS project is to integrate robotic systems with existing manned technology into European defence forces adding a new capability that will overmatch our adversaries’ abilities," said Kuldar Väärsi, CEO of Milrem Robotics. He noted that iMUGS will contribute to the strategic autonomy of the European Union and strengthen the cooperation between the member states.

During the first demonstration consortium partners showcased how the THeMIS can be deployed onto the battlefield using common Armoured Personnel Carriers (APC) and teamed with unmanned aerial systems. Specific technology used were the Boxer APC by Krauss-Maffei Wegmann (KMW) and a tethered drone by Acecore Technologies. A multirotor drone by Atlas Dynamics was also part of the scenario.

Altogether two scenarios were played out in cooperation with the Estonian Defence Forces.

In the first scenario the THeMIS integrated with Acecore’s tethered drone was operated Beyond the Line of Sight (BLOS) by the soldiers and used to detect and target an enemy position. After determining the target indirect fire was ordered and after-action review performed using the drone footage.

The purpose of the second scenario was to retrieve a casualty from a crashed vehicle and afterwards retrieve the vehicle. Both actions were performed with the THeMIS UGV while the Boxer towed the UGV into the mission area and Atlas’ drone provided overwatch and situational awareness.

“The demonstration confirmed that we have the interaction between manned and unmanned systems, as well as the interaction of hardware and software, under control,” said Thomas Reining, iMUGS Project Manager in Krauss-Maffei Wegmann.

The requirements for the standardized UGS have been set by seven EU member states: Estonia, the leader of the project, and Belgium, Finland, France, Germany, Latvia, and Spain.

“All of the participating nations have shown great interest in contributing to the development of the European UGS,” said Martin Jõesaar, iMUGS project officer in the Estonian Centre for Defence Investments. “The countries understand that they have to grow with the industry to integrate this kind of new technology rapidly and guide the industry towards the best solutions.”

iMUGS is a cooperation between 13 parties: Milrem Robotics (project coordinator), Talgen Cybersecurity, Safran Electronics & Defense, NEXTER Systems, Krauss-Maffei Wegmann, Diehl Defence, Bittium, Insta DefSec, (Un)Manned, dotOcean, Latvijas Mobilais Telefons, GMV Aerospace and Defence, and Royal Military Academy of Belgium.

Watch the Demo 1 Scenario 1 here - https://youtu.be/wAQHPdmm48M

Watch the Demo 1 Scenario 2 here - https://youtu.be/2vobuDOcfDA

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye